BMS Aims To Unseat Otezla In Psoriasis With US FDA-Approved Sotyktu

TYK2 Inhibitor Grows Bristol’s Immunology Franchise

 
• By Mandy Jackson
Start up concept with businessman holding briefcase and standing in front of rocket shaped gap in wall, revealing sunlit New York city view
BMS hired a whole new dermatology sales team to market Sotyktu • Source: Shutterstock

More from New Products

More from Scrip